Table 1.
Patient | Sex | Age (y) | Gene | Cobalamin resp | Presentation | Number of AMD per patient year | Number of samples | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Targeted analysis clinical laboratory | Targeted metabolic assays | Untargeted DI-HRMS in plasma | Untargeted DI-HRMS in DBS | |||||||||||||||
Total | No AMD | AMD | Total | No AMD | AMD | Total | No AMD | AMD | Total | No AMD | AMD | |||||||
P.01 | F | 19.6 | MUT | No | Early | 0.4 | 217 | 46 | 19 | 96 | 43 | 5 | 20 | 11 | 1 | 15 | 0 | 1 |
P.02 | M | 11.9 | MUT | No | Late | 0.9 | 43 | 28 | 0 | 69 | 59 | 0 | 20 | 19 | 0 | 11 | 10 | 0 |
P.03 | F | 11.0 | MUT | Yes | Late | 0.1 | 6 | 6 | 0 | 18 | 17 | 1 | 8 | 8 | 0 | 7 | 7 | 0 |
P.04 | F | 7.2 | MUT | No | Late | 0.5 | 1 | 1 | 0 | 2 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
P.05 | M | 7.5 | MUT | Yes | Late | 2.1 | 1 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
P.06 | F | 20.2 | MMAA | Yes | Early | 0.1 | 79 | 52 | 1 | 76 | 59 | 1 | 18 | 14 | 0 | 7 | 7 | 0 |
P.07a | F | 16.2 | MMAA | Yes | Early | 0.1 | 87 | 37 | 2 | 57 | 41 | 0 | 6 | 4 | 0 | 3 | 3 | 0 |
P.08a | M | b, 0.3 | MMAA | Yes | Late | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
P.09 | M | 13.9 | MMAA | Yes | Late | 0.1 | 7 | 7 | 0 | 7 | 7 | 0 | 2 | 2 | 0 | 2 | 2 | 0 |
P.10 | F | 11.1 | MMAA | Yes | Late | 0.1 | 44 | 0 | 3 | 60 | 1 | 1 | 13 | 0 | 1 | 19 | 1 | 1 |
P.11 | F | 40.6 | MMAB | Yes | Late | 0.0 | 25 | 10 | 0 | 16 | 11 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
P.12 | M | 0.1 | MUT | No | Early | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
P.13 | M | 37.3 | MMA, unclass | Yes | Early | 0.0 | 0 | 0 | 0 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
510 | 187 | 25 | 435 | 240 | 8 | 90 | 60 | 2 | 64 | 30 | 2 | |||||||
P.14 | F | 23.1 | PA, unclass | Early | 0.6 | 369 | 18 | 38 | 106 | 3 | 14 | 18 | 0 | 2 | 7 | 0 | 1 | |
P.15a | F | b, 2.9 | PA, unclass | Early | 4.1 | 33 | 28 | 3 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
P.16a | M | 12.5 | PA, unclass | Family | 2.4 | 92 | 6 | 19 | 21 | 3 | 3 | 9 | 1 | 2 | 13 | 0 | 2 | |
P.17 | F | 17.6 | PCCB | Early | 0.7 | 206 | 6 | 23 | 92 | 0 | 9 | 29 | 9 | 4 | 24 | 0 | 4 | |
P.18 | F | 17.9 | PCCA | Early | 0.7 | 251 | 64 | 31 | 128 | 50 | 12 | 37 | 11 | 4 | 30 | 0 | 4 | |
P.19 | F | 8.6 | PCCB | Early | 2.6 | 157 | 5 | 36 | 14 | 1 | 3 | 9 | 1 | 3 | 7 | 0 | 2 | |
P.20 | M | b, 7.5 | PCCB | Early | 0.3 | 0 | 0 | 0 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
P.21 | F | 24.6 | PCCA | Late | 0.2 | 16 | 0 | 0 | 7 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
P.22a | M | b, 19.1 | PCCB | Late | 0.3 | 80 | 1 | 2 | 72 | 2 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | |
P.23a | M | 19.1 | PCCB | Family | 0.1 | 62 | 32 | 4 | 61 | 32 | 1 | 19 | 9 | 0 | 11 | 0 | 0 | |
P.24 | M | 20.4 | PCCA | Late | 0.2 | 11 | 0 | 1 | 7 | 0 | 0 | 4 | 0 | 0 | 3 | 0 | 0 | |
1277 | 160 | 157 | 527 | 91 | 42 | 139 | 23 | 15 | 95 | 0 | 13 |
Subtotals are depicted in bold. aP.07 and P.08, P.15 and P.16, and P.22 and P.23 are pairs of siblings. Early onset: presentation < 28 days of life; Late onset: presentation > 28 days of life. Family: diagnosis at birth through an affected sibling. Abbreviations: AMD acute metabolic decompensation, F female, M male, unclass genetic defect is unclassified, (y) years; bpassed away